In this class action insider trading case, Pomerantz, as Co-Lead Counsel, achieved a $ 135 million settlement for
investors in the pharmaceutical company Elan Corp..
Not exact matches
Activist hedge fund
investor and recent Valeant
Pharmaceuticals (vrx) board appointee Bill Ackman on Wednesday slammed the
company's steep drug price hikes
in testimony before the U.S. Senate Special Committee on Aging, going so far as to say the cost bumps «contributed to healthcare inflation and called into question the
company's commitment to the patients it serves.»
The
investors are frustrated that shares
in Jazz, a $ 9 billion
pharmaceutical company known for its narcolepsy drug Xyrem, have remained essentially flat over the past year.
Pomerantz is co-lead counsel
in a securities class action against international
pharmaceutical company Perrigo plc concerning allegations related to the
company misleading
investors as to its revenue growth potential
in order to encourage them to reject a tender offer by Mylan N.V.
He represents
pharmaceutical companies both large and small on a myriad of issues, as well as several universities
in both patenting and licensing to outside
investors.
Art has over 30 years of operating experience as a
pharmaceutical and biotechnology industry executive and venture capital
investor in life science
companies.
«We are pleased to share this vision with the unique blend of crossover funds,
pharmaceutical companies, and venture capital
investors participating
in our Series B, and look forward to advancing our position as the leading biotech with a dual focus on synthetic lethality and immuno - oncology.»
The FDA is relevant for
investors specifically
in regards to biotech and
pharmaceutical companies.
In healthcare, Pfizer and other
pharmaceutical companies have lined up one - off funding for the development of specific products, matching their capital needs with the risk preferences and expertise of individual
investors.
Some
investors argue that massive share - price increases
in 2014 mean that even future successes won't produce strong returns for shareholders buying
in at today's prices, but the demand among top
pharmaceutical companies for promising drug candidates to add to their pipelines shows few signs of slowing anytime soon, and that could bode well for the sector
in the coming year.
Among some of the major homegrown
companies that Enterprise
Investors assisted and that went public on the WSE were the First Polish - American Bank
in 1994,
pharmaceuticals company Polfa Kutno
in 1995 and packaging manufacturer Grupa Kęty
in 1996.
Now,
in the IMS Health case, a big part of explaining why
investors might take such a deal is that it offered a nice premium over the recent stock price and they might have been comparing IMS Health to
pharmaceutical companies (IMS Health's customers) instead of
pharmaceutical services
companies (IMS Health's peers).
The so - called «Pharma Bro,» notorious for raising the price of a potentially life - saving drug by 5,000 percent, was found guilty today of defrauding
investors in two hedge funds and
in Retrophin Inc., a
pharmaceutical company he co-founded.
In a sign of the growing enthusiasm for the field, in March GRAIL, a company spun off from Illumina, raised $ 900 million in funding for this last application from investors including Amazon and several major pharmaceutical companie
In a sign of the growing enthusiasm for the field,
in March GRAIL, a company spun off from Illumina, raised $ 900 million in funding for this last application from investors including Amazon and several major pharmaceutical companie
in March GRAIL, a
company spun off from Illumina, raised $ 900 million
in funding for this last application from investors including Amazon and several major pharmaceutical companie
in funding for this last application from
investors including Amazon and several major
pharmaceutical companies.
Art has over 30 years of operating experience as a
pharmaceutical and biotechnology industry executive, and venture capital
investor in life science
companies.
The Vanguard Health Care Fund
Investor Shares (VGHCX) offers
investors low - cost exposure to domestic and foreign
companies involved
in various aspects of the health care industry, such as
pharmaceutical firms, medical supply
companies and research firms.
In a separate letter to the Corporate Secretary of the
Company, the
Investor is simultaneously submitting a Stockholder's Notice of Nomination of Persons for Election as Directors and Other Proposed Business at the 2009 Annual Meeting of Stockholders of Vanda
Pharmaceuticals Inc., dated February 13, 2009 (the «Notice»).
Which has its pros & cons:
Investors mostly adjust accordingly (i.e. reverse out some / all of this intangible expense), which explains why intellectual property
companies (as
in technology, media,
pharmaceuticals, etc.) often trade on steep earnings multiples vs. the rest of the market.
Investor documents from the
company that makes Nuedexta, Avanir
Pharmaceuticals, indicate that only a small percentage of people with PBA reside
in long - term care facilities.
acted as counsel and advocate for a Chinese
pharmaceutical company in HKIAC proceedings seated
in Hong Kong arising from a dispute with a foreign
investor
Mr. Girard currently serves on the leadership team
in the Target and Sony data breach actions; serves as lead counsel
in derivative litigation on behalf of Wal - Mart shareholders arising out of alleged bribery
in Mexico, lead counsel for commodities
investors in litigation arising out of the collapse of a commodities futures merchant, and lead counsel
in a multi-district «pay for delay» antitrust proceeding against major
pharmaceutical companies.
The reports also indicate that
investors are
in fact buying Galaxy Digital's shares through a shell
pharmaceutical company which will allow Novogratz's firm to be listed on a Canadian stock exchange without disclosing its financials.